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We retrospectively analyzed 42 hepatitis C virus (HCV)-
infected patients who underwent cadaveric liver trans-
plantation under two strategies of immunosuppression: 
(1) dailytacrolimus (TAC) throughout and an initial cycle 
of high-dose prednisone (PRED) with subsequent gradual 
steroid weaning, or (2) intraoperative antithyrnocyte 
globulin (ATG) and daily TAC that was later space 
weaned. After 36 ± 4 months, patient and graft survival in 
the first group was 18/19 (94.7%) with no examples of 
clinically serious HCV recurrence. In the second group, 
the three-year patient survival was 12123 (52%), and graft 
survival was 9/23 (39%); accelerated recurrent hepatitis 
was the principal cause of the poor results. The data were 
interpreted in the context of a recently proposed immu-
nologic paradigm that is equally applicable to transplan-
tation and viral immunity. In the framework of this par-
adigm, the disparate hepatitis outcomes reflected different 
equilibria reached under the two immunosuppression 
regimens between the relative kinetics of viral distribution 
(systemically and in the liver) and the slowly recovering 
HCV-specific T-cell response. As a corollary, the aims of 
treatment of the HCV-infected liver recipients should be 
to predict, monitor, and equilibrate beneficial balances 
between virus distribution and the absence of an immu-
nopathologic antiviral T-cell response. In this view, favor-
able equilibria were accomplished in the nonweaned 
group of patients but not in the weaned group. In conclu-
sion, since the anti-HCV response is unleashed when 
immunosuppression is weaned, treatment protocols that 
minimize disease recurrence in HCV-infected allograft 
recipients must balance the desire to reduce immunosup-
pression or induce allotolerance with the need to prevent 
antiviral immunopathology. (Liver Transpl 2005;11: 
1343-1352.) 
I n hepatic transplant recipients whose chronic liver disease had been caused by hepatitis B virus (HBY), 
:lCcelerated recurrence of chronic hepatitis l was almost 
llniversaJ2 until the development ofHBV-specific anti-
viral therapy.3 More recentlv, chronic hepatitis C virus 
(HCV) has emerged as the leading indication tor liver 
transplantation worldwide. Without treatment compa-
rable to that for HBV, disease ',ecurrence in HCV-
infected recipients 'cas reached ep!demic proportions 
and threatens to swamp iiver cemersK~ Donor ,ma recip-
ient risk factors that contribute to posnransplant HCV 
recurrence have been identified,',G but there has been 
no consensus about optimal immunosuppression for 
these patiencsJ,9 
We addressed the dilemma of optimal immunosup-
pression with a retrospective analysis of 42 patients with 
chronic HCV hepatitis who underwent liver replace-
ment under alternative management strategies duting 
2001-2002. The outcomes were remarkably different 
with the two strategies of immunosuppression. The 
data available in these patients were too incomplete to 
independently formulate a mechanism-based explana-
tion for the difference. However, here we describe and 
discuss the results in our patients from the point of view 
of a previously proposed immunologic paradigm that 
takes into account antigen kinetics, the antigen-specific 
T-cell responses to the viral and donor antigens, and the 
susceptibility of the respective responses to the different 
immunosuppressive regimens. lO- 12 The courses of 51 
uninfected liver recipients treated with one or the other 
strategy during the same period were similarly analyzed. 
Patients and Methods 
Patient Populations 
The 42 patients comprised all adult primary cadaveric liver 
recipients whose transplantations were for chronic HCV hep-
atitis between August 2001 and August 2002, except for 6 
who were excluded because of HI V co-infection. Only one of 
the 42 donors had evidence of a prior HeV infection by 
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Table l. Population Characteristics 
HCY Positive HCY Negative 
TAC-PRED ATG-TAC TAC-PRED ATG-TAC 
No. of patients 19 23 28 23 
Recipient age (yr) 513:!: 6.1 50.8 :2: 7.2 55.9 :2: 9.0 54.6 :!: 8.3 
Female (%) 26 43 39 57 
African-American (%) 0 0 0 4 
Mean MELD Score at Tx 16.4 :!: 5.5 13.4:!:4.4 19.4:: 7.9 16.0 :!: 5.5 
Donor age (yr) 44.1 :: 16.7 47.9:!: 16.3 44.1 :!: 19.4 41.3 :!: 18.3 
Female (%) 47 61 29 48 
African-American (%) 16 14 9 4 
Cold ischemic time (hours) 10.3 ± 2.4 9.9 :!: 2.2 11.3 :!: 3.2 9.1:: 2.2 
Mean HLA mismatch 4.4 :!: 1.0 4.4 ::':: 1.1 4.7 ::':: 1.0 4.9 :!: 0.8 
Abbreviations: HCY, hepatitis C virus: TAC, cacrolimus: PRED, prednisone; ATG, antithymocyte globulin; MELD, Model for 
End-Stage Liver Disease; Tx, transplantation; HLA, human leukocyte antigen. 
An analysis of variance by ANOYA revealed that significant differences in the population parameters of the 4 cohorts were limited to the 
MELD Score (P = 0.009) and ischemic time (P = 0.024). The conclusions reached in the evaluation of the results were not changed 
when adjusted fot these population differences. 
serologic testing. With the objective of facilitating natural 
tolerance mechanisms, [2 23 of these recipients were lym-
phoid-depleted with antithymocyre globulin (ATG, thymo-
globulin) prior to allograft revascularization and treated after 
transplantation with tacrolimus (TAC) monotherapy from 
which weaning was ultimately attempted. 13 The other 19, 
including the only recipient of a liver from a donor with 
positive HCV serology, were immunosuppressed continu-
ously with TAC and decremental doses of prednisone 
(PRED). 
Both protocols of immunosuppression were judged by the 
University of Pittsburgh Institutional Review Board to be 
within the boundaries of standard treatment and then 
remanded to the Presbyterian University Hospital Innovative 
Practices Committee and to the Pharmacy & Therapeutic 
Committee with approval by both. The protocol used in 
individual cases was selected by combined patient and sur-
geon choice. The decision was strongly influenced by the time 
available for a preoperative ATG infusion and by specific 
potential contraindications for the ATG medication (e.g., 
hepatopulmonary syndrome). All patients provided informed 
consent. In addition, separate informed consent was obtained 
for studies of immune variables not routinely obtained in our 
conventional practice. In compliance with our long-otanding 
institutional policy, data integrity and safety and efficacy 
monitoring were assured by establishment of a formal review 
every week of all cases. 
During the same one-vear period beginning in August 2001, 
all 51 adult primary cadaveric liver recipients who were not 
ing:E~cted with HCV were treated with one or the other immuno-
suppression protOcol. None of these donors had positive HCV 
serology or other evidence of a primary intection. Thus, 4 non-
r:U1domized groUDS could be defined by the choice of immuno-
suppression and the presence or absence of preexisting HCV 
disease: HCV-positive/TAC-PRED (n :: 19), HCV-positivel 
ATG-TAC (n = 23), HCV-negative/TAC-PRED (n :: 28), 
and HCV-negative/ATG-TAC (n = 23). 
Donor and recipient factors that have been reported to 
influence liver transplant outcome, with or without HCV, are 
summarized for the 4 groups in Table 1. The conclusions 
reached in the evaluation of the results were not changed 
when adjusted for differences in the various donor and recip-
ient characteristics. 
Immunosuppression 
TAC-PRED 
TAC was administered twice daily from the first postoperative 
day onward with a target 12-hour trough blood concentration 
of 10 ng/ mL. After the lif$[ several months, lower trough 
levels were considered acceptable. At one and two years, the 
trough levels averaged 8.6 :!: 3.1 and 6.6 :!: 3.0 ng/mL, 
respectively. Steroid treatment was begun intraoperatively 
with an infusion of 1 or 2 g methylprednisolone, followed by 
a 3- to 5-day postoperative course in which the daily methyl-
prednisolone (or oral PRED) quantities were reduced step-
wise from 200 to 20 mg. With further gradual steroid wean-
ing, 34 (74%) of the patients were offPRED or in the range of 
5-7.5 mg/day by the end of 3 months. At 12 months, 29 
(63%) of the 46 surviving patients were steroid free, and at 24 
months, 36 (84%) of the 43 survivors were off steroids. 
ATG-TAC 
The patients were infused with approximately 5 mg/kg rabbit 
ATG with co-infusion of 1-2 g methylprednisolone. On (he 
first postoperative day, TAC monotherapy was begun in the 
same way ~s in the TAC-PRED groups. Neither PRED nor 
other agents (e.g., mvcophenolate mofetil, sirolimus, or 
L 
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muromonab-CD3 rOKT3]) were added, singly or in combi-
nation, unless there was a breakthrough rejection. After 4 to 6 
monrhs, patiems who had been on stable tacrolimus mono-
therapy for at least 2 months had extension of the interval 
between TAC doses ("spaced weaning") to once a day, every 
other day, or longer if this was compatible with stable graft 
function. 
Viral and Donor Leukocyte Antigen Loads 
HCY Rt"lA concentrations were performed in our hospital 
using the Roche Amplicor HCV Monitor 2.0 (Roche Diag-
nostics, Basel, Switzerland) and other comparable assays, or at 
a reference laboratory using the Heptimax test (Quest Diag-
nostics, Teterboro, NJ). Samples were obtained as clinically 
indicated rather than by protocoL Details are provided in 
Results. 
In 20 of the patients immunosuppressed with ATG-TAC, 
donor leukocyte macro- or microchimerism was assessed in 
peripheral venous blood with previously described flow cyro-
metric, cyrospin, andlor polymerase chain reaction (PCR) 
techniques, 14 Confirming earlier observations,14.16 there was 
a declining incidence of blood macro- or microchimerism 
between 1 and 12 months, 
Distinction of Rejection and HCV Recurrence 
The differential diagnosis of rejection and HCV recurrence 
was made by strict adherence to previously described his-
topathologic criteria17 in biopsies obtained because of abnor-
malities in liver function tests. The courses of all patients not 
biopsied were reviewed and found to have no evidence of 
serious biochemical abnormalities, In the treatment-defined 
HCV subgroups, the number of biopsies in patients treated 
with ATG-TAC averaged 6.6 ± 3.2 vs, 3,1 ± 2.2 in those 
treated with TAC-PRED. For final diagnosis of individual 
biopsies, pathologists correlated the histopathologic findings 
with those in previous biopsies and with clinical observations 
including response to immunosuppression and HCY RNA 
levels, Thirty-one histological parameters including liver 
fibrosis (i,e., none, mild, moderate, or severe) were scored for 
each allograft biopsyY Scoring for hepatitis activity index 
and staging fibrosis were done for allograft biopsies diagnosed 
as recurrent HCY. 
Statistical Analysis 
An honest brokering system approved by the University of 
Pittsburgh IRB was used for data management Data were 
extracted, reviewed, augmented (where required) for accuracy 
and completeness, and de-identified for statistical analysis. 
Differences in means and standard deviations calculated from 
participants' characteristics by treatment group were evalu-
ated for statistical significance using XC tests for categorical 
comparisons and t tests and one-way analysis of variance for 
continuous comparisons. Kaplan-Meier survival curves were 
generated and evaluated for significance using a log-rank test 
for patient survival, graft survival, rejection, and time to HCY 
recurrence. Cox proportional hazards models were used to 
adjust survival comparisons for relevant covariates. A P value 
of <0,05 two sided was considered significant. The conclu-
sIOns reached in the evaluation of the results using unadjusted 
comparisons were not affected by adjusting for differences in 
the patient and donor populations. 
Results 
Patient and Graft Survival 
All patients were followed to the time of death or to 
March 1, 2005. The three-year survival of HCV-in-
fected recipients and of their primary grafts is 94.7% 
with the TAC-PRED strategy (Fig. lA). The patient 
survival with the ATG-TAC protocol is 52% and graft 
survival is 39% (P < 0.004) (Fig. IB). The postopera-
tive day and proximate cause of all graft losses and 
patient deaths in both groups are summarized in Table 
2. The higher loss rate during the first month in the 
ATG-TAC group was not obviously associated with 
recurrent HCV disease. However, 9 of the 11 subse-
quent failures were directly attributable to recurrent 
chronic hepatitis. In contrast, there were no examples of 
disease recurrence that led to hepatic insufficiency in 
the patients immunosuppressed with the TAC-PRED 
strategy. The mean serum bilirubin in the surviving 
patients who still bear their primary grafts was not sig-
nificantly different in the two treatment groups (see 
subscripts in Fig. 1). 
After the first 9 days, patient and graft survival in the 
contemporaneous uninfected patients was similar 
under both kinds of immunosuppression (Fig. 1 C-D) 
with causes of failure that were much the same (Table 
2). 
Time of HCV Recurrence or Rejection 
Recurrent Disease 
Prior to transplantation, serum HCV RNA concentra-
tions were comparable (and low) in both immunosup-
pression-defined groups of infected patients (Fig. 2A 
and Table 3), Afterwards, there was a rapid rise that was 
greater and longer lasting under ATG-TAC (Fig. 2A). 
The viral load out to three years has remained 1 O-fold or 
more higher than before transplantation in both immu-
nosuppression groups, When immunosuppression was 
augmented in response to the diagnosis of rejection, 
there were secondary increases. Conversely, treatment 
with pegylated interferon and ribavirin frequently 
resulted in a reduction in HCV level, most markedly in 
a small number of patients with HCV other than geno-
type 1. As previously reported, 18.19 there was no appar-
ent association of antiviral treatment with rejection. 
1'1 
I 
I 
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Figure 1. Patient and graft survival (months). Patient (black diamonds) and graft (gray squares) survival to three years for 
HCV-infected liver recipients (top panels) and uninfected recipients (bottom panels) under the TAC-PRED and ATG-TAC 
immunosuppression regimens. The Pvalues calculated by log-rank between the charts show that all other survival results were 
similar except in HCV-positive recipients under ATG-TAC immunosuppression. The current mean serum bilirubin of 
surviving primary grafts in the different groups (subscripts) is not significandy different. Horizontal axis in months. 
Table 2 Time (Days) and Causes of Graft Loss in HCY-Infected and Uninfected Recipients Under Two Kinds of 
Immunosuppression* 
Immune Primary Dysfunction Non-HCY 
Suppression n or Nonfunction Recurrent HCY Sepsis Other 
HCV-infected 
TAC-FRED 19 None None None G8lt 
ATG-TAC 23 1, 2, 10, 19 11 0, 308, 411, None 111:j:, 
508,761,797, 932§ 
865,874, 1,077 
Not HCV-infected 
TAC-PRED 28 5 NA 35,493 579 I 
ATG-TAC 23 2,9,9 NA 75, 171 IBM 
Abbreviations: HCY, hepatitis C virus; TAC, tacrolimus; FRED, prednisone; ATG, anrithymocyte globulin. 
'The bolded numbers indicate current patient sun'ival after retransplanration. 
I tDisseminated merastases from small hepatoma ill excised native liver. 
tMotor vehicle accident. 
I §Atherosderotic heart disease. : Gunshot suicide. !LJ.cemtion femorai artery during radiographic procedure. I 
I 
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Figure 2. The effect of two strategies of immunosuppres-
sion (TAC-PRED and ATG-TAC) in HCV-infected liver 
recipients (continuous lines of A-D). The dashed lines in 
C and D also depict the hepatic fibrosis scores and time to 
first rejection in noninfected contemporaneous liver 
recipients. Note that severe hepatic fibrosis occurred only 
in the HCV-infected patients treated with ATG-TAC (C). 
Horizontal axis in months. 
Antiviral Therapy 
The policy at our institution in 200 1-2002 was to con-
sider HCV-infected liver recipients for interferon-based 
therapies on an individualized basis. Treatment was 
deferred until recovery from the surgery and stabiliza-
tion of immunosuppression, and was not given in the 
presence of acute graft rejection and infections or in 
patients with no biochemical, clinical, or histopatho-
logic evidence of liver damage. Treatment was not given 
to any patient during the first 12 postoperative weeks. 
Once initiated, the protocol called for a 48-week 
course. 
Of the 23 patients immunosuppressed with ATG-
TAC 10 were treated at some time between 3 and 24 
months compared with 8 of the 19 in the T AC-PRED 
group, All but 4 of the 18 treated patients were given 
one subcutaneous dose per week of 1 ,l.Lg/kg PEG-In-
tron (Schering-Plough, Kenilworth, NJ) in combina-
tion with daily oral doses of 800 mg ribavirin. The 
starting dose of ribavirin was adjusted to as low as 200 
mg per day (e.g., in response to anemia) or escalated 
when feasible up to 1,200 mg per day. Erythropoietin 
and filgrasrim were administered as needed for anemia 
and leucopenia, respectively. In the 4 exceptional 
patients (all ATG-TAC), interferon treatment was ini-
tiated with three subcutaneous doses per week of 3 
million units IntronA (Schering-Plough), combined 
with the ribavirin schedule as described above. After 4 
and 12 weeks, two of the 4 patients were switched to 
one dose per week PEG-Intron. The other two were 
switched after 6 and 11 months to 180 ,l.Lg per week 
subcutaneous Pegasys (Roche Pharmaceuticals). 
Histopathologic evidence of disease recurrence in 
HCV-infected recipients occurred much earlier under 
ATG-TAC than with TAC-PRED immunosuppression 
(Fig. 2B). By two years, the degree of fibrosis (mild, mod-
erate, or severe), regardless of its location, was greater in 
those treated withATG-TAC (Fig. 2C, solid lines). 
Rejection 
Clarification of the extent to which the fibrosis was due 
to disease recurrence required analyses of rejection. The 
histopathologic diagnosis of rejection was made earlier 
and more frequently in patients treated with ATG-
TAC than in those under TAC-PRED in both the 
study group of HeV-infected patients and in the con-
temporaneous HCV-free recipients (Fig. 2D). Hepatic 
fibrosis scores of the uninfected recipients treated with 
ATG-TAC were no worse than those of the infected 
and uninfected recipients treated with TAC-PRED 
(Fig. 2C, compare solid and dashed lines). There 
were no graft losses or late chronic rejections under 
either kind of immunosuppression regardless of the 
HCV status. 
Temporal Associations 
In HCV-infected recipients whose grafts survived 
more than a month (19 in each treatment group), the 
virus genotype, HCV titer before transplantation, 
and the maximum titer during the first two years 
were similar in the ATG-TAC and TAC-PRED 
groups (Table 3). The incidence and duration of 
antiviral treatment were also similar, but the onset of 
this treatment was earlier in the ATG-TAC patients 
because of their propensity for earlier recurrence. 
The higher incidence of acute rejection in weaned 
patients who originally were treated with ATG-T AC 
resulted in a large percentage of patients who 
were then "rescued" with delayed alemruzumab 
(Campath). In these recipients, however, an increase 
in hepatitis activity and staging fibrosis already was 
present by the time of the alemtuzumab rescue 
(Table 3). Thus, the primary risk factot for recur-
-
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Table 3. Comparison of the Parients in the Two Immunosuppression-Defined HCV-Infected Subpopulations Whose Grafts 
Survived >30 Days 
ATG-TAC TAC-PRED 
(original n = 23) (original n = 19) 
Grafts surviving at 1 month 19 19 
HCV genotype 1 14/17 (82%) 11114 (79%) 
HCV tirer (logw IU/mL) 
Pretransplant titer 4.97 ::': 1.04 4.35 ::': 1.34 
Maximum titer first year 6.8 ::': 0.78 6.1 ::': 1.09 
Posttransplant antiviral treatment 
Number rreared within 2 years 10/19 S/19 
Onset treatment (months) 6.2 :+:: 2.3 12.4 ::': 4.S 
Duration treatment (months) 15.2:+:: 9.1 13.1 :+:: 3.0 
Time to spaced dose weaning (months) 4.4 :': 1.5 nla 
Acute rejection 
Preweaning 3/16 nla 
Posrweaning 10116 nla 
Hepatic staging fibrosis (0-6 scale) 
Preweaning* 0.6 :+:: O.SI nla 
Posrweaningt 2.3 :': 1.19 nla 
Hepatitis activity index (0-18 scale) 
Preweaning* 3.2 ::': 2.56 nla 
Posrweaningt 4.8 ::': 1.94 nla 
Later antirejecrion treatment 
Received steroid bolus after 1 year (n) 8119 3/19 
Received alemtuzumab rescue (n) 8/19 1/19 
Time to alemtuzumab rescue (months) 11.9 :+:: 4.2 10.5 
Abbreviations: ATG, antithymocyre globulin; TAC, racrolimus; PRED, prednisone; HCV, hepatitis C virus. 
'From biopsy 0 ro 2 months before the start of spaced-dose weaning. 
tFrom biopsy 3 to 5 months after the start of spaced-dose weaning. 
rence was the weaning, rather than the rescue ther-
apy. 
Maintenance Immunosuppression 
ATG-TAC 
Two of the 19 surviving HCY-free patients treated with 
ATG-TAC have been off all immunosuppression for 
more than a year. Ten more are on spaced doses of 
tacrolimus monotherapy: every other day (n = 2), three 
times per week (n = 5), and rwo times per week (n = 3). 
Of the other 7, 5 are on daily tacrolimus monotherapy 
and only 2 receive an additional immunosuppressant. 
One of the 11 HCY-infected patients who still 
survive after ATG-TAC treatment has been off all 
immunosuppression for more than a year. Five oth-
ers are on spaced doses of tacrolimus onlv: three 
times per week (n = 1), two times per week (n = 1), 
one time per week (n = 1), and every two weeks (n = 
2). Of the other 5, three are on daily tacrolimus 
monotherapy and two receive an ~ldditional immu-
nosuppressant. 
TAe-PRED 
No attempt was made to space wean tacrolimus in 
either the infected or uninfected patients treated with 
the TAC-PRED protocol. The greater long-term expo-
sure to a calcineurin-inhibitor drug was reflected in the 
43 currently surviving recipients of these two groups by 
a 9.3% incidence of renal dialysis or transplantation 
and a 29% incidence of hypertension vs. rates of 3.3% 
and 16% in the 30 survivors treated with ATG-TAe. 
Discussion 
Although it may be assumed that HCY recurred 
promptly in every patient,20 clinically significant man-
ifestations were almost completely avoided our to three 
years in our HCV-infected liver recipients who were 
immunosuppressed throughout with daily doses of 
tacrolimus to which prednisone was added in large 
doses for the first 5 postoperative days and slowly 
weaned thereafter. The competing strategy of intraop-
erative lymphoid depletion, steroid avoidance, and later 
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Figure 3. (A) Interrelation of non cytopathic anti-
gen quantity and the antigen-specific cytolytic 
T-cell (CTL) response after a primary HCV infec-
tion or, alternatively, after primary liver transplan-
tation. (B) Liver transplantation (Tx) in a patient 
with chronic aggressive hepatitis long after the 
viral/CTL balance shown in panel A is reached. 
The potential effect of immunosuppression on the 
quantity of the preexisting viral antigen, the de 
novo transplant antigen, and their respective CTL 
responses are shown schematically and described in 
the text. Horizontal axis = time. 
A 
t 
B 
weaning from tacrolimus mono therapy clearly pro-
moted life-threatening HCV disease recurrence. An 
explanation of the disparate results begins with consid-
eration of basic mechanisms. 
The presence of a surgically revascularized organ 
transplant is recognized only when the graft's passenger 
leukocytes migrate to host lymphoid organs where a 
donor-specific cytolytic T lymphocyte (CTL) response 
is induced. In the same way, a pathogen-specific 
response is induced by the hematogenous spread to 
lymphoid organs of the noncytopathic HCV.I0.21-23 
The activated CTL then target cells displaying com-
plexes of major histocompatibility complex (MHC) 
molecules plus peptides derived from the specific anti-
gen.24.25 The targeted cells of the hepatitis victim are 
heavily concentrated in the liver. With transplantation, 
all of the allogeneic cells of an organ may be targets. In 
most experimental liver transplant models and in 
humans, the donor-specific CTL of a nonimmunosup-
pressed recipient acutely reject the peripheralized donor 
leukocytes as well as the "nonself' parenchymal cells of 
the source hepatic allograft. Thus, rejection of the con-
stituent cells of a liver allograft is comparable to the 
destruction ofH CY -infected liver cells during a bout of 
acute infectious hepatitis. In either case, the live antigen 
mav persist in small quantities in protected nicbes, peri-
odically move to lymphoid organs, and stimulate con-
tinued antigen-specific immunity. 1 1.12.21 
Alternatively, the T-cell response may be exhausted 
and deleted during the first few weeks of maximum 
antigen distribution. 15,16.21.2G Perpetuation of the 
resulting nonreactive state depends on the persistence 
of sufficient amigen with access to host lymphoid 
organs. IUl,21 Residual antigen is therefore a two-edged 
,l>nt,1 gen 10 ad 
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sword, the effects of which may range from ongoing 
low-grade immunity (perhaps equivalent in some cases 
to memory) to the other extreme of durable deletional 
tolerance. Between these extremes, various balances 
may be reached between the amount of mobile cells 
expressing "nonself' antigen and the number of anti-
gen-specific CTL. 
In our reference immunologic paradigm, these bal-
ances are manifested by a diversity of transplant out-
comes and by analogous virus carrier syndromes, all of 
which represent different degrees of partial toler-
ance. 11 ,12 Such immunologic "compromises" include 
chronic allograft rejection and its analog, chronic hep-
atitis. From this perspective, it is apparent that the 
typical HCV-infected patient who comes to hepatic 
replacement after years or decades of slowly evolving 
liver damage is variably tolerant to the virus at the time 
strong transplant-related immunosuppression is 
started. In contrast, the allograft induces a de novo 
donor-specific response (Fig. 3). 
Both immunosuppression strategies used in our 
infected patients clearly disequilibrated the preexisting 
balance between HCY-specific CTL and virus quan-
tity. However, the resulting viremia was succeeded by 
severe bridging fibrosis only in the lymphoid-depleted 
patients who were systematically space weaned. With 
weaning of these recipients, large numbers of infected 
liver cells expressing HCY peptides apparently were 
destroyed by reemerging HCV-specific CTL (Fig. 3). 
Whether infected or not, the lymphoid depleted and 
weaned patients had a high incidence of rejection, 
which was caused by tbe separate and distinct donor-
specific CTL. In the majorirv of uninfected recipients 
treated with ATG-T-\c' exhaustion and deletion of the 
I 
I 
I 
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antidonor response was manifested by the ability to 
variablv space wean without graft loss or chronic rejec-
tion. Whereas the comparably treated HCY-infected 
recipients suffered an exorbirant mortality from accel-
erated disease recurrence, the rate-spaced weaning that 
was accomplished without chronic rejection in those 
who remained was similar to that in the uninfecred 
recipients. 
Why didn't accelerated HCY disease recurrence 
develop under TAC-PRED despite the proviral effect 
of the large initial amount of perioperative and posmp-
erative steroids? This can be explained as follows. In 
these patients, the relatively light double drug immu-
nosuppression reached by the sixth postoperative day 
(i.e., twice daily tacrolimus doses and prednisone doses 
of 20 mg/day) was further reduced only by cautious 
steroid weaning. The continuous immunosuppression 
presumably controlled the independent donor-specific 
and HCY-specific CTL responses, allowing establish-
ment of stable balances between these CTL and the 
respective antigens. 
Ie should be emphasized that the TAC-PRED pro-
tocol employed in these patients was identical to the 
steroid-sparing strategy used when tacrolimus was 
introduced clinically27,28 and before that when cyclo-
sporine was the baseline agent. 29 When the historical 
strategy was systematically applied in individual cen-
ters, 5- and 1 O-year survivals were essentially the same as 
in uninfected patients.30-52 The dire consequences of 
Hey infection subsequently documented in multi-
center registries coincided with a worldwide movement 
to more complex regimens in which three or more 
drugs were administered for protracted periods from 
the time of transplamation. 4,5,7,33 Although this kind of 
heavy prophylactic therapy greatly reduces the inci-
dence of acute rejection, we previously have suggested 
that the resulting excessive immunodepression can 
subvert the seminal mechanism of allograft-induced 
tolerance (i.e., clonal exhaustion-deletion) and thereby 
comribute to long-term immunosuppression depen-
dence. 1 1.11 
How these multi agent promcols also may promote 
accelerated HCY disease recurrence in the same way as 
in our ATG-TAC cohort of recipients can be readily 
envisioned, Both the ATG-TAC protocol and the reg-
imens of multiple-drug prophylactic immunosuppres-
sion cause viremia. In rum, the magnirude and duration 
of viremia has been associated with the onset and sever-
ity of disease recurrence. j4 Such observations have 
prompted speculation bv some authorities that the nor-
mallv noncytopathic HCY may become cytotoxic.>' 
However, in the paradigm llsed to interpret our clinical 
results, the viremia that is inevitable with any effective 
immunosuppression is neither cytotoxic nor the critical 
factor per se. 
Instead, the treatment outcome depends on the 
effect of the immunosuppression on the overall balance 
between virus distribution and immune responsive-
ness. 12 When high-dose multiple-drug strategies are 
instituted at the time of transplantation, reduction 
and/or discontinuance of one or more constituents of 
the "cocktail" ultimately becomes obligatory to avoid 
the lethal risk of prolonged general immunodepression. 
The cells of the transplanted liver, which presumably 
have been heavily infested in proportion to the extent of 
the immunosuppression-induced viremia, are then tar-
geted by the slowly recovering HCY-specific CTL as 
well as by the slowly recovering donor-specific CTL 
whose efficient activation ---;> exhaustion-deletion has 
been precluded by the early heavy treatment. 12 If recov-
ery of the independent HCY-directed and graft-di-
rected CTL responses occurs out of phase and the iso-
lated diagnosis of HCY recurrence is made at this 
juncture, the instinctive decision to abruptly reduce 
immunosuppression may make the recurrence worse in 
the same way as occurred with spaced weaning in the 
ATG-TAC cohort (Fig. 3). 
Thus, the optimum immunosuppression for HCY-
infected liver recipients is contingent on its timing and 
continuity, not the avoidance of a specific drug or drugs 
(including steroids and the lymphoid-depleting 
agents), In this view, the aims of treatment of a recipient 
with HCY disease should be to predict, monitor, and 
equilibrate beneficial balances between virus distribu-
tion and the absence of an immunopathological anti-
HCVT-cell response. The TAC-PRED protocol exem-
plifies how these objectives are achievable, The initial 
vety short course of high doses of preemptive pred-
nisone protects the graft from irreversible damage from 
acute rejection, followed by extremely cautious and 
gradual steroid weaning. If over-immunosuppression is 
scrupulously avoided after the first few days, interfer-
ence with donor-specific tolerogenesis may be mini-
mized, allowing low levels of maintenance immunosup-
pression to be ptomptly reached. 12,13 
Other protocols with different drug combinations 
that include antilymphoid antibodies may yield good 
results if these therapeutic principles are applied, For 
example, Eason et al. observed no degradation of results 
after a mean follow-up of 18.5 months in a large series 
of HCY-infected patients treated perioperatively with 
ATG and managed therearter with an absolutely ste-
roid-free posttransplant regimen of daily tacrolimus 
that was never weaned. 56 Although (he results with the 
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generalizable approach to Immunosuppression exem-
plified by our TAC-PRED group of recipients can be 
gratifying, the limitations of the strategy are obvious. 
These include a lifetime commitment to a relatively 
fixed level of daily immunosuppression and the epide-
miologic implications of producing HCV carrier recip-
ients. Further improvements will require the same steps 
that led to the control of HBV. The highest public 
health priority is the development of an effective vac-
cine to protect health care providers and others at risk. 
For infected liver transplant candidates, the foremost 
objective is containment of the viral load with yet to be 
developed HCV-specific drugs: e.g., the protease inhib-
itor described by Reiser et al.37 An alternative option is 
the development of better neutralizing anti-HCV anti-
bodies.38.39 
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